Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development.

Request For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2847

Market Dynamics

New strategies adopted by key players related to outsourcing drug discovery is expected to drive growth of global outsourced drug discovery market. For instance, in June 2019, GlaxoSmithKline (GSK), a British drug manufacturing company collaborated with the University of California to establish a state-of-the-art laboratory for CRISPR technologies, the Laboratory for Genomics Research (LGR), in San Francisco. The new laboratory will investigate how gene mutations cause diseases, and also develop new technologies using CRISPR to rapidly accelerate the discovery of new medicines.

Furthermore, extension of partnership activities is expected to propel global outsourced drug discovery market growth. For instance, in March 2017, Charles River Laboratories (CRL) extended its partnership with Chiesi Farmaceutici. Under this partnership, Charles River Laboratories (CRL) extended its longstanding, strategic, integrated drug discovery program (Respiratory Program). The respiratory program is related to the preclinical drug development for treatment of respiratory diseases and rare diseases.

Increasing number of drug discovery companies is expected to drive growth of the global outsourced drug discovery market

Increasing number of new drug discovery companies is expected to drive the global outsourced drug discovery market growth. For instance, in November 2018, Schrodinger, LLC collaborated with Wuxi AppTec and launched new drug discovery company, Faxian Therapeutics (Headquarter– New York, U.S.). Faxian Therapeutics will utilize the Schrodinger, LLC’s computational platform and WuXi’s drug design and synthesis services to improve health care needs.

Global Outsourced Drug Discovery Market - Competitive Landscape

Key players operating in the global outsourced drug discovery market are Aurigene Accelerating Discovery, Bioduro LLC, Charles River Laboratories (CRL), Chempartner, TCG Lifesciences, Evotec AG, Syngene International Ltd., Jubilant Biosys Ltd, Pharmaron Inc., Shanghai Medicilon, and Sundia Meditech Co. Ltd.

Detailed Segmentation:

Global Outsourced Drug Discovery  Market, By Drug Type:

Small Molecule Drugs

Large Molecule Drugs

Global Outsourced Drug Discovery market, By Services:

Preclinical Development

Target Validation and Functional Informatics

Target Identification and Screening

Lead Identification and Candidate Optimization

Others

Global Outsourced Drug Discovery Market, By Application

Oncology

Ophthalmology

Hematology

Immunomodulation

Anti-Infective Drugs

Dermatology

Pulmonology

Cardiology

Others

Global Outsourced Drug Discovery market, By End User

Pharmaceutical and Biotechnological Companies

Contract Research Organization

Contract Manufacturing Organization

Global Outsourced Drug Discovery Market- Regional Analysis

North America outsourced drug discovery market is expected to account for the largest market share, owing to business expansion in this region. For instance, in January 2019, Lambda Therapeutic Research (Headquarter-India) acquired Novum Pharmaceutical Research Services, a U.S. CRO. With this acquisition, Lambda Therapeutic Research entered into the U.S. market.

Moreover, Europe is also projected to witness significant growth in the global outsourced drug discovery market, owing to increasing merger and acquisition activities by key players in the region. For instance, in February 2019, Optimapharm, a clinical research organization (CRO) in Europe acquired Denothex, a CRO, for strengthening its presence in the European market particularly in France, Spain, Switzerland, and Italy. Denothex conducts all clinical trials in oncology across Europe and Israel.

Asia Pacific is also projected to witness significant growth in the global Outsourced Drug Discovery Market, owing to increasing launches of IT infrastructure investment programs (Trial Management and Monitoring Cloud Service Implementation Program) for development of clinical trials. For instance, in December 2018, Novotech, a CRO, launched new Oracle Trial Management and Monitoring Cloud Service Implementation Program (TMMCS) in Asia-Pacific.TMMCS helps to maintain centralized trial management database and clinical research associate productivity. TMMCS provides various benefits including better trial results, improved investigator relationship, and lower trial costs.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]